Literature DB >> 31907823

Astragaloside IV ameliorates intermittent hypoxia-induced inflammatory dysfunction by suppressing MAPK/NF-κB signalling pathways in Beas-2B cells.

Jian-Kun Chen1,2, Ming-Kai Guo1,2, Xiao-Hui Bai1,2, Li-Qin Chen1,2, Shun-Mei Su1,2, Li Li3, Ji-Qiang Li4,5.   

Abstract

PURPOSE: Intermittent hypoxia is a characteristic pathological change in obstructive sleep apnoea (OSA) that can initiate oxidative stress reaction and pro-inflammatory cytokine release. The purpose of this study was to assess the effect and protective mechanism of Astragaloside IV (AS-IV) in intermittent hypoxia-induced human lung epithelial Beas-2B cells.
METHODS: Human lung epithelial Beas-2B cells were exposed to intermittent hypoxia or normoxia in the absence or presence of AS-IV. MTT assay was performed to determine the cell viability. The levels of reactive oxygen species (ROS), lactate dehydrogenase (LDH), malonaldehyde (MDA), and superoxide dismutase (SOD) were measured to evaluate oxidative stress. The levels of cytokines interleukin (IL)-8, IL-1β, and IL-6 were evaluated by enzyme-linked immunosorbent assay and real-time PCR. The expression of Toll-like receptor 4 (TLR4), mitogen-activated protein kinase (MAPK), and nuclear transcription factor-kappa B (NF-κB) signalling pathways was analysed by western blot.
RESULTS: The results showed that AS-IV significantly reduced the levels of ROS, LDH, MDA, IL-8, IL-1β, and IL-6, and increased the level of SOD in intermittent hypoxia-induced Beas-2B cells. It also suppressed the phosphorylation of MAPKs, including P38, c-Jun N-terminal kinase and extracellular signal-regulated kinase, and inhibited the activation of the NF-κB signalling pathway by reducing the phosphorylation of IκBα and p65.
CONCLUSIONS: AS-IV attenuates inflammation and oxidative stress by inhibiting TLR4-mediated MAPK/NF-κB signalling pathways in intermittent hypoxia-induced Beas-2B cells.

Entities:  

Keywords:  Astragaloside IV; Intermittent hypoxia; NF-κB; Obstructive sleep apnoea

Year:  2020        PMID: 31907823     DOI: 10.1007/s11325-019-01947-8

Source DB:  PubMed          Journal:  Sleep Breath        ISSN: 1520-9512            Impact factor:   2.816


  6 in total

1.  Astragaloside IV alleviates placental oxidative stress and inflammation in GDM mice.

Authors:  Ling Zhou; Ruixue Zhang; Shuangyan Yang; Yaguang Zhang; Dandan Shi
Journal:  Endocr Connect       Date:  2020-10       Impact factor: 3.335

2.  Outer Membrane Vesicles Derived from Klebsiella pneumoniae Influence the miRNA Expression Profile in Human Bronchial Epithelial BEAS-2B Cells.

Authors:  Federica Dell'Annunziata; Concetta Paola Ilisso; Carmela Dell'Aversana; Giuseppe Greco; Alessandra Coppola; Francesca Martora; Fabrizio Dal Piaz; Giuliana Donadio; Annarita Falanga; Marilena Galdiero; Lucia Altucci; Massimiliano Galdiero; Marina Porcelli; Veronica Folliero; Gianluigi Franci
Journal:  Microorganisms       Date:  2020-12-13

3.  Neuroprotective Effect of Astragaloside IV on Cerebral Ischemia/Reperfusion Injury Rats Through Sirt1/Mapt Pathway.

Authors:  Yi-Hua Shi; Xi-Le Zhang; Peng-Jie Ying; Zi-Qian Wu; Le-Le Lin; Wei Chen; Guo-Qing Zheng; Wen-Zong Zhu
Journal:  Front Pharmacol       Date:  2021-03-26       Impact factor: 5.810

4.  Silencing MR-1 Protects against Myocardial Injury Induced by Chronic Intermittent Hypoxia by Targeting Nrf2 through Antioxidant Stress and Anti-Inflammation Pathways.

Authors:  Qixue Wang; Yue Wang; Jiner Zhang; Shuo Pan; Shaofeng Liu
Journal:  J Healthc Eng       Date:  2022-01-03       Impact factor: 2.682

5.  Protective effect of Astragaloside IV on chronic intermittent hypoxia-induced vascular endothelial dysfunction through the calpain-1/SIRT1/AMPK signaling pathway.

Authors:  Fang Zhao; Yan Meng; Yue Wang; Siqi Fan; Yu Liu; Xiangfeng Zhang; Chenyang Ran; Hongxin Wang; Meili Lu
Journal:  Front Pharmacol       Date:  2022-08-02       Impact factor: 5.988

Review 6.  Natural Compounds for SIRT1-Mediated Oxidative Stress and Neuroinflammation in Stroke: A Potential Therapeutic Target in the Future.

Authors:  Chaoyou Fang; Houshi Xu; Ling Yuan; Zhengyang Zhu; Xiaoyu Wang; Yibo Liu; Anke Zhang; Anwen Shao; Meiqing Lou
Journal:  Oxid Med Cell Longev       Date:  2022-09-05       Impact factor: 7.310

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.